Rituximab therapy for severe refractory chronic Henoch-Schönlein purpura.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 19559299.
- Also identified by DOI 10.1016/j.jpeds.2008.12.049.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To report on the efficacy of rituximab (RTX) therapy in standard treatment-refractory, chronic Henoch-Schönlein purpura, a retrospective chart review of 3 pediatric patients treated with RTX for severe refractory chronic Henoch-Schönlein purpura was performed. All 3 patients responded to 1 or 2 courses of RTX without serious adverse events.
Medical subject headings
- Antibodies, Monoclonal
- IgA Vasculitis
- Immunologic Factors